Identification

Name
Lopinavir
Accession Number
DB01601  (EXPT00388)
Type
Small Molecule
Groups
Approved
Description

Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.

Structure
Thumb
Synonyms
  • LPV
External IDs
A-157378-0 / A-157378.0 / ABT-378
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2006-04-11Not applicableUs
KaletraLopinavir (200 mg) + Ritonavir (50 mg)TabletOralAbbvie2006-09-08Not applicableCanada
KaletraLopinavir (100 mg/1) + Ritonavir (25 mg/1)Tablet, film coatedOralAbbvie2010-06-18Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralRemedy Repack2008-06-092017-01-18Us
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralAbbvie2010-06-18Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralDispensing Solutions, Inc.2010-06-18Not applicableUs
KaletraLopinavir (133.3 mg) + Ritonavir (33.3 mg)CapsuleOralAbbvie2001-03-092012-11-02Canada
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralDoh Central Pharmacy2009-07-01Not applicableUs
KaletraLopinavir (200 mg/1) + Ritonavir (50 mg/1)Tablet, film coatedOralRebel Distributors2010-06-18Not applicableUs
KaletraLopinavir (80 mg) + Ritonavir (20 mg)SolutionOralAbbvie2001-03-09Not applicableCanada
International/Other Brands
Aluviran / Koletra
Categories
UNII
2494G1JF75
CAS number
192725-17-0
Weight
Average: 628.8008
Monoisotopic: 628.362470666
Chemical Formula
C37H48N4O5
InChI Key
KJHKTHWMRKYKJE-SUGCFTRWSA-N
InChI
InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
IUPAC Name
(2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES
CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1

Pharmacology

Indication

Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.

Associated Conditions
Pharmacodynamics

Lopinavir is an antiretroviral of the protease inhibitor class. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.

Mechanism of action

Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles.

TargetActionsOrganism
AHuman immunodeficiency virus type 1 protease
inhibitor
Human immunodeficiency virus 1
Absorption

Administered alone, lopinavir has insufficient bioavailability; however, like several HIV protease inhibitors, its blood levels are greatly increased by low doses of ritonavir, a potent inhibitor of cytochrome P450 3A4.

Volume of distribution
Not Available
Protein binding

Lopinavir is highly bound to plasma proteins (98-99%).

Metabolism

Hepatic. Lopinavir is extensively metabolized by the hepatic cytochrome P450 system, almost exclusively by the CYP3A isozyme.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Although human experience of acute overdosage with lopinavir is limited, accidental ingestion of the product by a young child could result in significant alcohol-related toxicity and could approach the potential lethal dose of alcohol.

Affected organisms
  • Human Immunodeficiency Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Lopinavir.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Lopinavir.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lopinavir.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lopinavir.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Lopinavir.Approved, Investigational
AbemaciclibThe risk or severity of adverse effects can be increased when Lopinavir is combined with Abemaciclib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Lopinavir.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Lopinavir.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Lopinavir.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Lopinavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lopinavir.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Lopinavir can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Lopinavir.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Lopinavir.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Lopinavir.Approved
AgmatineThe metabolism of Agmatine can be decreased when combined with Lopinavir.Experimental, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lopinavir.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Lopinavir.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Lopinavir.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Lopinavir.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Lopinavir.Experimental, Investigational
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Lopinavir.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Lopinavir.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Lopinavir.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Lopinavir.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Lopinavir.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Lopinavir.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Lopinavir.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Lopinavir.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Lopinavir.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Lopinavir.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Lopinavir.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Lopinavir.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Lopinavir.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Lopinavir.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lopinavir.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Lopinavir.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Lopinavir.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Lopinavir.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Lopinavir.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Lopinavir.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Lopinavir.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Lopinavir.Approved, Investigational
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Lopinavir.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Lopinavir.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Lopinavir.Approved
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Lopinavir.Approved, Vet Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Lopinavir.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Lopinavir.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Lopinavir.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Lopinavir.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Lopinavir.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Lopinavir.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Lopinavir.Approved, Investigational
ApalutamideThe serum concentration of Apalutamide can be increased when it is combined with Lopinavir.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Lopinavir.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Lopinavir.Approved, Investigational
AprepitantThe serum concentration of Lopinavir can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Lopinavir.Approved
AranidipineThe metabolism of Aranidipine can be decreased when combined with Lopinavir.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Lopinavir.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Lopinavir.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Lopinavir.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Lopinavir.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Lopinavir.Investigational
AtazanavirThe metabolism of Lopinavir can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Lopinavir.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Lopinavir is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Lopinavir.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Lopinavir.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Lopinavir.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Lopinavir.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Lopinavir.Approved, Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lopinavir.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Lopinavir.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Lopinavir.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Lopinavir.Approved
Beclomethasone dipropionateThe metabolism of Beclomethasone dipropionate can be decreased when combined with Lopinavir.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Lopinavir.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lopinavir.Investigational
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Lopinavir.Experimental
BenidipineThe metabolism of Benidipine can be decreased when combined with Lopinavir.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Lopinavir.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Lopinavir.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Lopinavir.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Lopinavir.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Lopinavir.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Lopinavir.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Lopinavir.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Lopinavir.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Lopinavir.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Lopinavir.Approved, Experimental
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Lopinavir.Approved, Investigational
BoceprevirThe serum concentration of Lopinavir can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Lopinavir.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Lopinavir.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Lopinavir.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Lopinavir.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Lopinavir.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Lopinavir.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Lopinavir.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Lopinavir.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Lopinavir.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Lopinavir.Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Lopinavir.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Lopinavir.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Lopinavir.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Lopinavir.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Lopinavir.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Lopinavir.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Lopinavir.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Lopinavir.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Lopinavir.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Lopinavir.Approved, Nutraceutical
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Lopinavir.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Lopinavir.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Lopinavir.Approved
CarbamazepineThe serum concentration of Lopinavir can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Lopinavir.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Lopinavir.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Lopinavir.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Lopinavir.Approved, Investigational
CarisoprodolThe metabolism of Carisoprodol can be increased when combined with Lopinavir.Approved
CaroverineThe metabolism of Caroverine can be decreased when combined with Lopinavir.Experimental
CarteololThe metabolism of Carteolol can be decreased when combined with Lopinavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Lopinavir.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Lopinavir.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Lopinavir.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Lopinavir.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Lopinavir.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Lopinavir.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Lopinavir.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Lopinavir.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Lopinavir.Approved
ChloramphenicolThe metabolism of Chloramphenicol can be increased when combined with Lopinavir.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
ChlormadinoneThe serum concentration of Chlormadinone can be decreased when it is combined with Lopinavir.Experimental
ChloroquineChloroquine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Lopinavir.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Lopinavir.Approved, Investigational
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Lopinavir.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Lopinavir.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Lopinavir.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lopinavir.Experimental
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Lopinavir.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Lopinavir.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Lopinavir.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Lopinavir.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Lopinavir.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Lopinavir.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Lopinavir.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Lopinavir.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Lopinavir.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Lopinavir.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Lopinavir.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Lopinavir.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Lopinavir.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Lopinavir.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Lopinavir.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Lopinavir.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Lopinavir.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Lopinavir.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Lopinavir.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Lopinavir.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Lopinavir.Approved, Illicit
ClotrimazoleThe metabolism of Lopinavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Lopinavir.Approved
CobicistatThe metabolism of Lopinavir can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Lopinavir.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Lopinavir.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Lopinavir.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Lopinavir.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Lopinavir.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Lopinavir.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Lopinavir.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Lopinavir.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Lopinavir.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Lopinavir.Approved
CurcuminThe metabolism of Lopinavir can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe metabolism of Cyclandelate can be decreased when combined with Lopinavir.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Lopinavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Lopinavir.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Lopinavir.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.Approved
DabrafenibThe serum concentration of Lopinavir can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Lopinavir.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Lopinavir.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Lopinavir.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Lopinavir.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Lopinavir.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Lopinavir.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Lopinavir.Experimental
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Lopinavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Lopinavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Lopinavir.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Lopinavir.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Lopinavir.Approved, Investigational
DeferasiroxThe serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Lopinavir.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Lopinavir.Approved
DelamanidLopinavir may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Lopinavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lopinavir.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Lopinavir.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Lopinavir.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Lopinavir.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Lopinavir.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Lopinavir.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Lopinavir.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Lopinavir.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Lopinavir.Approved, Investigational
DeutetrabenazineThe serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Lopinavir.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Lopinavir.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Lopinavir.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Lopinavir.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Lopinavir.Approved, Investigational
DexniguldipineThe metabolism of Dexniguldipine can be decreased when combined with Lopinavir.Experimental
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Lopinavir.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Lopinavir.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be decreased when combined with Lopinavir.Experimental
DiazepamThe metabolism of Diazepam can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Vet Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Lopinavir.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Lopinavir.Approved, Vet Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Lopinavir.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Lopinavir.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Lopinavir.Approved, Investigational
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Lopinavir.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Lopinavir.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Lopinavir.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lopinavir.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Lopinavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Lopinavir.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lopinavir.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lopinavir.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lopinavir.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lopinavir.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Lopinavir.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Lopinavir.Approved
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Lopinavir.Approved, Withdrawn
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Lopinavir.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Lopinavir.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Lopinavir is combined with Disulfiram.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Lopinavir.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Lopinavir.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Lopinavir.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Lopinavir.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Lopinavir.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Lopinavir.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Lopinavir.Investigational
DoxepinThe metabolism of Doxepin can be decreased when combined with Lopinavir.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Lopinavir.Approved, Investigational
DoxycyclineThe metabolism of Lopinavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Lopinavir.Approved, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Lopinavir.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Lopinavir.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lopinavir.Approved, Investigational
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Lopinavir.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Lopinavir.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Lopinavir.Approved
EfavirenzThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Lopinavir.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Lopinavir.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Lopinavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Lopinavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Lopinavir.Approved, Investigational
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Lopinavir.Approved
EmopamilThe metabolism of Emopamil can be decreased when combined with Lopinavir.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Lopinavir.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Lopinavir.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Lopinavir.Investigational
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Lopinavir.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Lopinavir.Experimental
EnzalutamideThe serum concentration of Lopinavir can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe metabolism of Eperisone can be decreased when combined with Lopinavir.Approved, Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Lopinavir.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Lopinavir.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Lopinavir.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Lopinavir.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Lopinavir.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lopinavir.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lopinavir.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Lopinavir.Approved
EribulinEribulin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Lopinavir.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lopinavir.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Lopinavir.Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Lopinavir.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Lopinavir.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Lopinavir.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Lopinavir.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Lopinavir.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Lopinavir.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Lopinavir.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Lopinavir.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Lopinavir.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Lopinavir.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Lopinavir.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Lopinavir.Approved
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Lopinavir.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Lopinavir.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Lopinavir.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Lopinavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Lopinavir.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Lopinavir.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Lopinavir.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Lopinavir.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Lopinavir.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Lopinavir.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Lopinavir.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Lopinavir.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Lopinavir.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Lopinavir.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Lopinavir.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Lopinavir.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Lopinavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Lopinavir.Approved, Investigational
Fish oilThe metabolism of Fish oil can be decreased when combined with Lopinavir.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Lopinavir.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Lopinavir.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Lopinavir.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Lopinavir.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Lopinavir.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Lopinavir.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Lopinavir.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Lopinavir.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Lopinavir.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Lopinavir.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Lopinavir.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Lopinavir.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
FluspirileneThe metabolism of Fluspirilene can be decreased when combined with Lopinavir.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Lopinavir.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Lopinavir.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Lopinavir.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Lopinavir.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Lopinavir.Approved
FluvoxamineThe metabolism of Lopinavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Lopinavir.Approved, Investigational
FosamprenavirThe serum concentration of Lopinavir can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Lopinavir can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Lopinavir.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Lopinavir.Approved
FosphenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Lopinavir.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Lopinavir.Approved, Investigational
Fusidic AcidThe serum concentration of Lopinavir can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe metabolism of Gabapentin can be decreased when combined with Lopinavir.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Lopinavir.Approved
GallopamilThe metabolism of Gallopamil can be decreased when combined with Lopinavir.Investigational
GarlicThe serum concentration of Lopinavir can be decreased when it is combined with Garlic.Approved, Nutraceutical
GefitinibThe metabolism of Gefitinib can be decreased when combined with Lopinavir.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Lopinavir.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Lopinavir.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Lopinavir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Lopinavir.Investigational, Withdrawn
GliclazideThe metabolism of Gliclazide can be increased when combined with Lopinavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Lopinavir.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Lopinavir.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Lopinavir.Approved, Investigational
GlucosamineThe metabolism of Glucosamine can be increased when combined with Lopinavir.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Lopinavir.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Lopinavir.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Lopinavir.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Lopinavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Lopinavir.Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Lopinavir.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Lopinavir.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Lopinavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Lopinavir.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Lopinavir.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Lopinavir.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Lopinavir.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Lopinavir.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Lopinavir.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Lopinavir.Approved, Vet Approved
Hydrocortisone acetateThe metabolism of Hydrocortisone acetate can be decreased when combined with Lopinavir.Approved, Vet Approved
Hydrocortisone butyrateThe metabolism of Hydrocortisone butyrate can be decreased when combined with Lopinavir.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Lopinavir.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Lopinavir.Approved, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Lopinavir.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lopinavir.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Lopinavir.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Lopinavir.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Lopinavir.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Lopinavir.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Lopinavir.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Lopinavir resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Lopinavir.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Lopinavir.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Lopinavir.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Lopinavir.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Lopinavir.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Lopinavir.Approved
IndinavirThe metabolism of Lopinavir can be decreased when combined with Indinavir.Approved
IndomethacinThe metabolism of Indomethacin can be increased when combined with Lopinavir.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lopinavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lopinavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lopinavir.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Lopinavir.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Lopinavir.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Lopinavir.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Lopinavir.Experimental
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Lopinavir.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Lopinavir.Approved, Investigational
IsavuconazoleThe serum concentration of Lopinavir can be decreased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Lopinavir.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Lopinavir.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Lopinavir.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Lopinavir.Investigational
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Lopinavir.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Lopinavir.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Lopinavir.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Lopinavir.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Lopinavir.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Lopinavir.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Lopinavir.Approved, Investigational
KetoconazoleThe serum concentration of Lopinavir can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Lopinavir.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Lopinavir.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Lopinavir.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Lopinavir.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Lopinavir.Approved, Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Lopinavir.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Lopinavir.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Lopinavir.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Lopinavir.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Lopinavir.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Lopinavir.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Lopinavir.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be decreased when combined with Lopinavir.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Lopinavir.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Lopinavir.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Lopinavir.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Lopinavir.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Lopinavir.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Lopinavir.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Lopinavir.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Lopinavir.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Lopinavir.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Lopinavir.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Lopinavir.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Lopinavir.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Lopinavir.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Lopinavir.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be decreased when combined with Lopinavir.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Lopinavir.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Lopinavir.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Lopinavir.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Lopinavir.Approved
LorpiprazoleThe serum concentration of Lopinavir can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Lopinavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Lopinavir.Approved, Investigational
LuliconazoleThe serum concentration of Lopinavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Lumacaftor can be increased when it is combined with Lopinavir.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Lopinavir.Approved
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Lopinavir.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Lopinavir.Approved, Investigational
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Lopinavir.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lopinavir.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Lopinavir.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Lopinavir.Approved
Magnesium sulfateThe metabolism of Magnesium sulfate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Lopinavir.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Lopinavir.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Lopinavir.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Lopinavir.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Lopinavir.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Lopinavir.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lopinavir.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Lopinavir.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Lopinavir.Approved, Investigational
Megestrol acetateThe serum concentration of Megestrol acetate can be decreased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
MelatoninThe metabolism of Melatonin can be increased when combined with Lopinavir.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Lopinavir.Vet Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Lopinavir.Experimental, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Lopinavir.Approved, Vet Approved
MentholThe metabolism of Menthol can be decreased when combined with Lopinavir.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Lopinavir.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be increased when combined with Lopinavir.Approved, Illicit
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Lopinavir.Approved, Vet Approved
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Lopinavir.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Lopinavir.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Lopinavir.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Lopinavir.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Lopinavir.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Lopinavir.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Lopinavir.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Lopinavir.Illicit, Withdrawn
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Lopinavir.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Lopinavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Lopinavir.Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be increased when combined with Lopinavir.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Lopinavir.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Lopinavir.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Lopinavir.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Lopinavir.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Lopinavir.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Lopinavir.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Lopinavir.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Lopinavir.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Lopinavir.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Lopinavir.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Lopinavir.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Lopinavir.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Lopinavir.Approved, Investigational
MifepristoneLopinavir may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Lopinavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Lopinavir.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Lopinavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Lopinavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Lopinavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lopinavir.Approved, Investigational
MitotaneThe serum concentration of Lopinavir can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Lopinavir.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Lopinavir.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Lopinavir.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Lopinavir.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Lopinavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Lopinavir.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lopinavir.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Lopinavir.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Lopinavir.Approved, Investigational
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Lopinavir.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Lopinavir.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Lopinavir.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Lopinavir.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Lopinavir.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Lopinavir.Approved, Withdrawn
NelfinavirThe serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Lopinavir.Approved, Investigational
NetupitantThe serum concentration of Lopinavir can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.Approved
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Lopinavir.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Lopinavir.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Lopinavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Lopinavir.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Lopinavir.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Lopinavir.Experimental
NilutamideThe metabolism of Nilutamide can be increased when combined with Lopinavir.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Lopinavir.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Lopinavir.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Lopinavir.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Lopinavir.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Lopinavir.Approved, Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Lopinavir.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Lopinavir.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Lopinavir.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Lopinavir.Approved, Investigational
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Lopinavir.Approved
NorgestrienoneThe serum concentration of Norgestrienone can be decreased when it is combined with Lopinavir.Experimental
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Lopinavir.Approved
NylidrinThe metabolism of Nylidrin can be decreased when combined with Lopinavir.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Lopinavir.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Lopinavir.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Lopinavir.Approved
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Lopinavir.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Lopinavir.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Lopinavir.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Lopinavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Lopinavir.Investigational
OpiumThe metabolism of Opium can be decreased when combined with Lopinavir.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Lopinavir.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Lopinavir.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Lopinavir.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Lopinavir.Experimental, Investigational
OxazepamThe metabolism of Oxazepam can be decreased when combined with Lopinavir.Approved
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Lopinavir.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Lopinavir.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Lopinavir.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Lopinavir.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Lopinavir.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Lopinavir.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Lopinavir.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Lopinavir.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Lopinavir.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Lopinavir.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Lopinavir.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Lopinavir.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Lopinavir.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Lopinavir.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Lopinavir.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Lopinavir.Approved
PenfluridolThe metabolism of Penfluridol can be decreased when combined with Lopinavir.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
PentobarbitalThe serum concentration of Pentobarbital can be increased when it is combined with Lopinavir.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Lopinavir.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Lopinavir.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Lopinavir.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Lopinavir.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Lopinavir.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Lopinavir.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Lopinavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Lopinavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Lopinavir.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Lopinavir.Approved
PhenobarbitalThe serum concentration of Lopinavir can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Lopinavir.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Lopinavir.Approved, Investigational
PhenytoinThe serum concentration of Lopinavir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Lopinavir.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Lopinavir.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Lopinavir.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Lopinavir.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Lopinavir.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Lopinavir.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Lopinavir.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Lopinavir.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Lopinavir.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Lopinavir.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Lopinavir.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Lopinavir.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Lopinavir.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Lopinavir.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Lopinavir.Approved, Investigational
PosaconazoleThe metabolism of Lopinavir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Lopinavir.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Lopinavir.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Lopinavir.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Lopinavir.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Lopinavir resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Lopinavir.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Lopinavir.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Lopinavir.Approved, Vet Approved
PregabalinThe metabolism of Pregabalin can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.Approved, Experimental, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Lopinavir.Withdrawn
PrimaquinePrimaquine may increase the QTc-prolonging activities of Lopinavir.Approved
PrimidoneThe serum concentration of Primidone can be increased when it is combined with Lopinavir.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Lopinavir.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Lopinavir.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Lopinavir.Approved
PromazinePromazine may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Lopinavir.Approved, Investigational
PropafenoneThe serum concentration of Lopinavir can be increased when it is combined with Propafenone.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Lopinavir.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Lopinavir.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Lopinavir.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Lopinavir.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Lopinavir.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Lopinavir.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Lopinavir.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Lopinavir.Approved, Investigational
QuingestanolThe serum concentration of Quingestanol can be decreased when it is combined with Lopinavir.Experimental
QuinidineLopinavir may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Lopinavir.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Lopinavir.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Lopinavir.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Lopinavir.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Lopinavir.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Lopinavir.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Lopinavir.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Lopinavir.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Lopinavir.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Lopinavir.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Lopinavir.Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Lopinavir.Approved
RibociclibThe serum concentration of Ribociclib can be increased when it is combined with Lopinavir.Approved, Investigational
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Lopinavir.Approved, Investigational
RifampicinThe risk or severity of adverse effects can be increased when Rifampicin is combined with Lopinavir.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Lopinavir.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Lopinavir.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Lopinavir.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Lopinavir.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Lopinavir.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Lopinavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Lopinavir.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Lopinavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Lopinavir.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Lopinavir.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Lopinavir.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Lopinavir.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Lopinavir.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Lopinavir.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Lopinavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Lopinavir.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Lopinavir.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Lopinavir.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Lopinavir.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Lopinavir.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Lopinavir.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Lopinavir.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Lopinavir can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Lopinavir.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be decreased when combined with Lopinavir.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Lopinavir.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Lopinavir.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Lopinavir.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Lopinavir.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Lopinavir.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.Approved
SiltuximabThe serum concentration of Lopinavir can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Lopinavir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Lopinavir.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Lopinavir.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Lopinavir.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Lopinavir.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Lopinavir.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Lopinavir.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lopinavir.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Lopinavir.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Lopinavir.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Lopinavir.Approved
St. John's WortThe metabolism of Lopinavir can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Lopinavir can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Lopinavir.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Lopinavir.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Lopinavir.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Lopinavir.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Lopinavir.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Lopinavir.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Lopinavir.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Lopinavir.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Lopinavir.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Lopinavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Lopinavir.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Lopinavir.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Lopinavir.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Lopinavir.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Lopinavir.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Lopinavir.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Lopinavir.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Lopinavir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Lopinavir.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Lopinavir.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Lopinavir.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Lopinavir is combined with Temsirolimus.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Lopinavir.Approved
Tenofovir disoproxilLopinavir may increase the nephrotoxic activities of Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Lopinavir.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Lopinavir.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Lopinavir.Experimental
TerodilineThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Lopinavir.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Lopinavir.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Lopinavir.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Lopinavir.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Lopinavir.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Lopinavir.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Lopinavir.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be decreased when combined with Lopinavir.Investigational
TetrandrineThe metabolism of Tetrandrine can be decreased when combined with Lopinavir.Experimental
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Lopinavir.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be increased when combined with Lopinavir.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Lopinavir.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Lopinavir.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Lopinavir.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Lopinavir.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Lopinavir.Approved, Investigational
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Lopinavir.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Lopinavir resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Lopinavir.Approved
TimololThe metabolism of Timolol can be decreased when combined with Lopinavir.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Lopinavir.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Lopinavir.Approved
TipranavirThe serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Lopinavir.Approved, Withdrawn
TizanidineTizanidine may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
TocilizumabThe serum concentration of Lopinavir can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Lopinavir.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Lopinavir.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Lopinavir.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Lopinavir.Approved, Investigational
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Lopinavir.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Lopinavir.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Lopinavir.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Lopinavir.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Lopinavir.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Lopinavir is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Lopinavir.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lopinavir.Approved, Investigational
TranilastThe metabolism of Tranilast can be decreased when combined with Lopinavir.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Lopinavir.Approved, Investigational
TrazodoneLopinavir may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Lopinavir.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Lopinavir.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Lopinavir.Approved, Investigational
TrimebutineThe metabolism of Trimebutine can be decreased when combined with Lopinavir.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Lopinavir.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Lopinavir.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Lopinavir.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Lopinavir.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Lopinavir.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Lopinavir.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Lopinavir.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Lopinavir.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Lopinavir.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Lopinavir.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Lopinavir.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Lopinavir.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Lopinavir.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Lopinavir.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Lopinavir.Approved, Investigational
VemurafenibThe serum concentration of Lopinavir can be decreased when it is combined with Vemurafenib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Lopinavir.Approved, Investigational
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Lopinavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Lopinavir.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Lopinavir.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Lopinavir.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Lopinavir.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Lopinavir.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Lopinavir.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Lopinavir.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Lopinavir.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Lopinavir.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Lopinavir.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Lopinavir.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Lopinavir.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Lopinavir.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Lopinavir.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Lopinavir.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Lopinavir.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Lopinavir.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Lopinavir.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be decreased when combined with Lopinavir.Experimental
YohimbineThe metabolism of Yohimbine can be decreased when combined with Lopinavir.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Lopinavir.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Lopinavir.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Lopinavir.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Lopinavir.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Lopinavir.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Lopinavir.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Lopinavir.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Lopinavir.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Lopinavir.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Lopinavir.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Lopinavir.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Lopinavir.Approved, Investigational
Food Interactions
  • Avoid St.John's Wort.
  • Take with food.

References

Synthesis Reference
US5914332
General References
Not Available
External Links
Human Metabolome Database
HMDB0015539
KEGG Drug
D01425
KEGG Compound
C12871
PubChem Compound
92727
PubChem Substance
46508588
ChemSpider
83706
BindingDB
578
ChEBI
31781
ChEMBL
CHEMBL729
Therapeutic Targets Database
DAP000708
PharmGKB
PA450264
HET
AB1
RxList
RxList Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Lopinavir
ATC Codes
J05AR10 — Lopinavir and ritonavir
PDB Entries
1mui / 1rv7 / 2o4s / 2q5k / 2qhc / 2rkf / 2rkg / 2z54 / 3ogq / 4l1a

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedOtherHealthy Volunteers1
0CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Lopinavir/Ritonavir1
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedOtherDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedOtherFenofibrate / Glucuronosyltransferase / Human Immunodeficiency Virus (HIV) / Hypertriglyceridemias / Protease Inhibitors1
1CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHepatitis C Viral Infection / Thrombocytopenias1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Pregnancy1
1CompletedTreatmentInsulin Resistance1
1CompletedTreatmentTuberculosis1
1SuspendedTreatmentHuman Immunodeficiency Virus (HIV)1
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1, 2CompletedTreatmentInfection, Human Immunodeficiency Virus I / Pf Subclinical Parasitemia1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
2CompletedTreatmentFibrosis, Liver / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections20
2RecruitingOtherHuman Immunodeficiency Virus (HIV) / Tuberculosis1
2TerminatedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Oligodendroglioma (AO) / Brain Stem Gliomas / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Mixed Gliomas / Neoplasms, Brain1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Viral Hepatitis B1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2WithdrawnTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentAcute HIV Infection1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pediatric AIDS1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pregnancy1
3Active Not RecruitingTreatmentAcute HIV Infection1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections4
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHIV-Infected Children1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)3
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections23
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentInfection, Human Immunodeficiency Virus I2
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3TerminatedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections2
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3WithdrawnTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Proteinuria1
4CompletedBasic ScienceCardiovascular Disease (CVD) / Dyslipidemias / Glucose Metabolism Disorders / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Diseases1
4CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
4CompletedDiagnosticAIDS-Related Opportunistic Infections / Human Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Tuberculosis1
4CompletedTreatmentHIV/AIDS Treatment / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHIV/HCV Co-infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHiv-positive / Malnourished1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)8
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections13
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipoatrophy1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Mitochondrial Toxicity1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)2
4RecruitingPreventionHIV/AIDS and Infections1
4RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Tuberculosis1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4TerminatedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections7
4Unknown StatusPreventionHIV-Associated Lipodystrophy Syndrome / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections4
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)3
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections6
Not AvailableCompletedNot AvailableInfection, Human Immunodeficiency Virus I3
Not AvailableCompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedOtherEndothelial Dysfunction1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections12
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Wasting Disease1
Not AvailableCompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentAIDS/HIV PROBLEM1
Not AvailableUnknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
Not AvailableWithdrawnTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentLymphoma, Hodgkins / Stage I Adult Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
SolutionOral
TabletOral
Tablet, film coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6703403Yes1996-12-262016-12-26Us
US6037157Yes1996-12-262016-12-26Us
US6232333Yes1998-05-072018-05-07Us
US7432294Yes2000-11-222020-11-22Us
US7141593Yes2000-11-222020-11-22Us
US5914332Yes1996-06-132016-06-13Us
US6284767Yes1996-08-152016-08-15Us
US7364752Yes2001-05-102021-05-10Us
US8309613Yes2005-06-242025-06-24Us
US8377952Yes2008-04-222028-04-22Us
US8691878Yes2005-02-252025-02-25Us
US8025899Yes2008-06-142028-06-14Us
US7148359Yes2000-01-192020-01-19Us
US8470347Yes2007-03-172027-03-17Us
US8268349Yes2005-02-252025-02-25Us
US8399015Yes2005-02-252025-02-25Us
US6458818Yes1998-05-072018-05-07Us
US6521651Yes1998-05-072018-05-07Us
US6911214Yes2002-05-282022-05-28Us
US8501219No2001-11-282021-11-28Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00192 mg/mLALOGPS
logP3.91ALOGPS
logP4.69ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)13.39ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area120 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity179.36 m3·mol-1ChemAxon
Polarizability69.2 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6593
Blood Brain Barrier-0.9916
Caco-2 permeable+0.8856
P-glycoprotein substrateSubstrate0.8755
P-glycoprotein inhibitor IInhibitor0.7355
P-glycoprotein inhibitor IIInhibitor0.5277
Renal organic cation transporterNon-inhibitor0.8578
CYP450 2C9 substrateNon-substrate0.7508
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6732
CYP450 1A2 substrateNon-inhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.7326
CYP450 2D6 inhibitorNon-inhibitor0.9438
CYP450 2C19 inhibitorNon-inhibitor0.7983
CYP450 3A4 inhibitorNon-inhibitor0.6469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9054
Ames testNon AMES toxic0.8049
CarcinogenicityNon-carcinogens0.7865
BiodegradationNot ready biodegradable0.9182
Rat acute toxicity2.2503 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8605
hERG inhibition (predictor II)Inhibitor0.8475
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-0119005000-e99616dc321beea979ae
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0532-1900601000-f85a252f1640f27563a8

Taxonomy

Description
This compound belongs to the class of organic compounds known as valine and derivatives. These are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Valine and derivatives
Alternative Parents
Amphetamines and derivatives / m-Xylenes / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Pyrimidones / Diazinanes / N-acyl amines / Secondary carboxylic acid amides / Ureas
show 7 more
Substituents
Valine or derivatives / Amphetamine or derivatives / Phenoxy compound / Phenol ether / M-xylene / Xylene / Alkyl aryl ether / Pyrimidone / Monocyclic benzene moiety / 1,3-diazinane
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dicarboxylic acid diamide, amphetamines (CHEBI:31781)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Aspartic-type endopeptidase activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72874
Uniprot Name
Pol polyprotein
Molecular Weight
10778.7 Da
References
  1. Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027]
  2. Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM: Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. J Med Chem. 2007 Sep 6;50(18):4316-28. Epub 2007 Aug 16. [PubMed:17696512]
  3. Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  5. Authors unspecified: Lopinavir/ritonavir: a protease inhibitor combination. Med Lett Drugs Ther. 2001 Jan 8;43(1095):1-2. [PubMed:11151088]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Lopez Aspiroz E, Cabrera Figueroa SE, Iglesias Gomez A, Valverde Merino MP, Dominguez-Gil Hurle A: CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman. Clin Drug Investig. 2015 Jan;35(1):61-6. doi: 10.1007/s40261-014-0245-7. [PubMed:25391550]
  2. Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 May;9(4):310-22. [PubMed:18473749]
  3. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD: Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006 May;42(1):52-60. doi: 10.1097/01.qai.0000219774.20174.64. [PubMed:16639344]
  4. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
  5. Sham HL, Betebenner DA, Herrin T, Kumar G, Saldivar A, Vasavanonda S, Molla A, Kempf DJ, Plattner JJ, Norbeck DW: Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4;11(11):1351-3. [PubMed:11378352]
  6. Drug Interactions & Labeling - FDA [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ: Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003 Mar;55(3):381-6. doi: 10.1211/002235702739. [PubMed:12724045]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...

Components:
References
  1. Drug Interactions & Labeling - FDA [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4. [PubMed:12700464]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Annaert P, Ye ZW, Stieger B, Augustijns P: Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010 Mar;40(3):163-76. doi: 10.3109/00498250903509375. [PubMed:20102298]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on August 29, 2007 12:45 / Updated on August 15, 2018 09:51